|

Unveiling the Germline Predisposition to Myeloproliferative Neoplasms

RECRUITINGSponsored by Fondazione IRCCS Policlinico San Matteo di Pavia
Actively Recruiting
SponsorFondazione IRCCS Policlinico San Matteo di Pavia
Started2022-06-27
Est. completion2030-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The classic Ph-negative myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic disorders caused by a dysregulated JAK/STAT signal transduction because of acquired somatic mutations of JAK2, CALR or MPL genes. They are sporadic diseases but there are several lines of evidence that support the role of germline factors in the pathogenesis of MPN: the existence of familial clustering, the presence of more than one clone in some patients, the known existence of common polymorphisms that cause predisposition to MPN. In this study, we would like to define the germline predisposition to MPN.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* A diagnosis of PV, ET, prePMF, overt PMF or MPN-U according to 2016 WHO criteria
* Characterization of the MPN driver mutation performed at any moment before enrolment
* diagnosis of MPN made when the patient was younger than 27 years old OR at least a second case of hematologic malignancies in first or second-degree relatives

Exclusion Criteria:

* None

Conditions3

CancerGermline MutationMyeloproliferative Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.